Pyrazolopyrimidines as CRF antagonists
 A compound of the formula: ##STR1## and the pharmaceutically acceptable acid addition salts thereof, wherein PA1 A is NR.sub.1 R.sub.2, CR.sub.1 R.sub.2 R.sub.11, or C(.dbd.CR.sub.1 R.sub.12)R.sub.2, NHCR.sub.1 R.sub.2 R.sub.11, OCR.sub.1 R.sub.2 R.sub.11, SCR.sub.1 R.sub.2 R.sub.11, NHNR.sub.1 R.sub.2, CR.sub.2 R.sub.11 NHR.sub.1, CR.sub.2 R.sub.11 OR.sub.1, CR.sub.2 R.sub.11 SR.sub.1 or C(O)R.sub.2 ; wherein the rest of the variables are herein below defined, used for inflammatory disorders. 
Pfizer Inc
A A A A A A C A A A A A A
A61P A61P A61P A61P A61P A61P C07D A61P A61P A61P A61P A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Yuhpyng Liang
Chen